Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: Exp Eye Res. 2007 Feb 11;84(5):922–933. doi: 10.1016/j.exer.2007.01.022

Figure 6. CNV reversal by intravitreal injection of AG013764 and AG013711.

Figure 6

Four groups of animals (n=25) were injected either with AG013764, AG013711 or control carrier solution for two weeks starting six weeks after AAV-VEGF injection. Methods as in Fig. 3D legend. Data from each pair of eyes are connected with a black line. The mean area of CNV in the AG013764 treated eyes (n = 13) was reduced by 57% (p < 0.005). The mean area of CNV in the AG013711 treated eyes (n = 12) was reduced by 60% (p < 0.05). The data points labeled 4A & 5A are from control eyes and 4D & 5D are from treated eyes. These four data points were obtained from the whole mount images shown in Figs 4 & 5.